A record turnover for Q2 2010 reflecting the successful US FDA approval

Paris, July 22, 2010 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announced a turnover of €15.2 million for the second quarter of 2010 versus €1.5 million in Q2 2009.

Turnover and Cash

This dramatic increase is directly linked to the successful approval of Loramyc® in the US under the brand name Oravig™ in April 2010, and upon which BioAlliance has received a $20 million milestone payment from its commercial partner, Strativa Pharmaceuticals, fully recognized as revenue (€14.8 million).

"The US approval of Oravig™ is a major step for BioAlliance Pharma that reflects the expertise of its teams", declares Dominique Costantini, CEO of BioAlliance Pharma. *"We are the only small and medium-sized innovative French Company to have a drug approved on the US market, the largest market worldwide. Our US partner, Strativa Pharmaceuticals, is actively preparing the launch of Oravig™ after the summer. BioAlliance has now some advanced products capable to generate global revenues and long-lasting growth".*

Beside this significant achievement, income from licensing agreements totaled €0.3 million. This includes notably royalties from Therabel on Loramyc® sales in France and the first supply of Oravig™ to the US partner, Strativa Pharmaceuticals.

BioAlliance Pharma cash reserves have been reinforced by the payments received from Therabel in March (for a total of €7.5 million) and from Strativa Pharmaceuticals in April (€14.8 million) and thus amount up to €28.9 million as of June 30, 2010. This total includes the reimbursement of the 2009 research tax credit of €1.8 million received in May. *"This increase in our cash reserves, with non-dilutive revenues from our licensing agreements, demonstrates the relevance of our strategic options, and allows us to fund our growth based on our product portfolio"*, underlines Nicolas Fellmann, Chief Financial Officer of BioAlliance Pharma.

Recent achievements

During the second quarter, BioAlliance Pharma has carried on discussions with Health Authorities and is planning the European registration file submission of acyclovir Lauriad® in mid-2011, based on the final positive results of its pivotal phase III clinical trial including more than 700 patients. In addition, the Company is pursuing the clinical development of three promising products in the areas of supportive care and orphan cancers: clonidine Lauriad® in radio- and chemo-induced oral mucositis, fentanyl Lauriad® in cancer chronic pain and AMEP®, a biotherapy in metastatic melanoma.

About BioAlliance Pharma

Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries and in the United States

Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries

Acyclovir Lauriad® (Labialis herpes): Positive phase III final results

Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results

AMEP® (Invasive melanoma): Phase I

Clonidine Lauriad® (Mucositis): Phase II

Doxorubicine Transdrug® (Liver cancer): Phase II

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Dominique Costantini, Directeur Général
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com